An observational study in Hepatocellular Cancer (HCC), sponsored by Zhongshan People's Hospital, Guangdong, China. Recruiting at 1 site in China. Open to participants aged 35 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-08.
Sponsored by Zhongshan People's Hospital, Guangdong, China · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 309 studies in Liver Neoplasms with a site in China — 122 open to participants now, 134 under way, 7 of them phase 3. Liver Neoplasms · China.
Among the 309 studies in Liver Neoplasms with a site in China, this one is the 8th largest by planned enrollment of the 74 observational ones that give a count, is one of 29 that started in 2025, is one of 74 observational ones, reaches primary completion later than 47 of the 133 other live ones, and was the 260th registered.
1,346 studies on the registry are indexed under Liver Neoplasms; 335 are open to participants now.
Browse Liver Neoplasms studies →122 of the 309 studies in Liver Neoplasms with a site in China are open now. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18–75
Hunan Cancer Hospital · Sites in China
Ages 45–74 · Healthy volunteers
West China Hospital · Sites in China
Ages 18–75
Beijing Municipal Administration of Hospitals · Sites in China
Ages 18+ · Healthy volunteers
Anhui Provincial Hospital · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 243 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 69 (28%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.
This study: 35 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
309 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 76 · Phase 2 80 · Phase 3 38 · Phase 4 17
First in 1983; this study’s year is marked. 29 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 4,500 is above the median of 200 across 343 observational studies indexed under Liver Neoplasms.
Median enrollment 80 across the 235 interventional studies, 305 across the 74 observational. Of the 84 that completed or were terminated, 12 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
63 of 309 have an industry lead sponsor. The 10 most frequent:
Zhongshan People's Hospital, Guangdong, China is the lead sponsor of 11 studies on the registry; 8 are open to participants now.
Zhongshan People's Hospital, Guangdong, China has 2 studies filed under Liver Neoplasms — fewer than ten, so there is no comparison to draw.
30 of the studies in Liver Neoplasms with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05794971Phase 3Sun Yat-sen UniversityRegorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases | 2027-03-31 |
| NCT07848750Beijing Municipal Administration of HospitalsInstaSure™ Non-Invasive Finger-Press Test for Hepatocellular Carcinoma | 2026-12-01 |
| NCT06173726BioSyngen Pte LtdInvestigator-initiated Phase I Exploratory Clinical Study of the Safety, Tolerability, and Efficacy of BST02 Injection in the Treatment of Locally Advanced/Metastatic Liver Cancer | 2026-12-05 |
| NCT07362264Nanjing Sanhome Pharmaceutical, Co., Ltd.A Study of SH006 Injection Combination Therapy in Patients With Advanced Solid Tumors | 2026-12-30 |
| NCT07053072West China HospitalPD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma. | 2026-12-30 |
Add all 30 to your calendar (.ics) → With an account.
Among the 309 studies in Liver Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Based on the preliminary retrospective validation of the efficacy of five HCC screening strategies(including conventional AFP combined with ultrasound-based general screening strategy, REACH-B, AGED, aMAPand aMAP 3.0 risk score) in Xiaolan Town, a head-to-head comparison for HCC screening is conducted in Zhongshan City, Guangdong Province. The study is a prospective, single-center, head-to-head trial aiming to enroll 4,500 HBsAg-positive individuals. It adopts a two-phase design of "HBV screening first, followed by HCC surveillance":Phase I: Recruitment of age-eligible populations at study sites for HBsAg screening to establish a high-risk cohort positive for hepatitis B surface antigen.Phase II: Implementation of uniform HCC surveillance (AFP combined with liver ultrasound every six months) for HBsAg-positive individuals, with concurrent application of different risk stratification models to evaluate risk levels and screening efficacy for each participant during follow-up.Furthurmore, based on baseline biological information and follow-up data, the study also aims to explore the development of a more effective risk prediction model for HCC.
Local household-registered residents aged ≥35 years, HBsAg-positive, with no prior diagnosis of HCC, residing in Zhongshan City.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Local household-registered residents aged 35-64 years who are HBsAg-positive and have not been diagnosed with HCC prior to enrollment, residing in the study site communities of Zhongshan City
Diagnostic Test: Quantitative HBeAg Testing · Biological: Measurement Indicators Required for Risk Scoring in HCC Screening Strategies · Biological: Follow-Up Monitoring Parameters
Quantitative HBeAg Testing in Population-Based Primary Screening
REACH-B: Age, Sex, HBeAg status, ALT levels, and HBV DNA load; AGED: Age, Sex, HBeAg status, HBV DNA load; aMAP: Age, Sex, Albumin, Total Bilirubin, Platelet Count; aMAP 3.0: Age, Sex, Albumin, Total Bilirubin, Platelet Count, AFP and PIVKA-II.
AFP, Liver Ultrasound
Incidence of HCC
The number of newly diagnosed HCC cases divided by total person-years at risk during follow-up for each screening strategy.
Time frame: 3 years
Predictive performance (Sensitivity, Specificity, Positive Predictive value, AUC, etc.)
Sensitivity, specificity, positive predictive value(PPV) and area under the ROC curve (AUC) will be calculated to evaluate the discrimination of each model.
Time frame: 3 years
Risk stratification accuracy
Participants will be categorized into different risk strata (high, intermediate, low) by each model, and their observed HCC incidence will be compared to assess stratification accuracy.
Time frame: 3 years
Screening positivity and referral rate
Proportion of participants identified as medium/high-risk and referred for further diagnostic imaging (e.g.,pathology/CT/MRI).
Time frame: 3 years
Stage distribution of HCC cases identified by different screening strategies
Time frame: 3 years
Early detection rate of HCC cases identified by different screening strategies
Time frame: 3 years
Number Needed to Screen (NNS)
Number of individuals needed to be screened to prevent one case of HCC.
Time frame: 3 years
Incremental Cost-Effectiveness Ratio (ICER)
The additional cost required to gain one extra QALY or to prevent one HCC case using a given model, compared with baseline strategy.
Time frame: 3 years
Time-dependent AUC or C-index
Model discrimination assessed at different time points using time-dependent ROC curves and concordance index (C-index).
Time frame: 3 years
Model performance in subgroups
Subgroup analyses to compare predictive performance of each model in different populations (e.g., by sex, age, ALT level, HBV DNA level).
Time frame: 3 years
Overall survival (OS)
Indicates whether the participant was alive at the end of follow-up and their survival duration.
Time frame: 3 years
Screening adherence
The proportion of participants who completed biannual AFP and ultrasound screenings as scheduled during follow-up.
Time frame: 3 years
Started Mar 2025 (actual). Primary completion is estimated for Dec 2025, 9 months after the start.
Of 132 non-industry observational studies under Liver Neoplasms, half reached primary completion within 114 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 172. This study's planned 9 months is below that.
Counting every sponsor, half of 160 studies reached it within 59 months; a quarter within 34 and three quarters within 172.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zhongshan People's Hospital, Guangdong, China